GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE
Glucotrack (Nasdaq: GCTK), a medical technology company focusing on diabetes technologies, will participate in the 2024 BioFuture Conference in New York City from October 28-30, 2024. Paul V. Goode, President & CEO, will present on October 29 at 11:00 AM ET, providing an update on the company's continuous blood glucose monitor (CBGM) development.
The BioFuture Conference will explore topics such as quantum computing in biology, alternative financing, AI in healthcare, psychedelics in mental health treatments, and bioethical challenges. Speakers from prominent companies like Regeneron Pharmaceuticals, IBM, and JP Morgan will discuss major trends shaping healthcare's future.
Qualified investors and media can apply for complimentary registration to attend the conference, which will feature over 100 future-focused presentations.
Glucotrack (Nasdaq: GCTK), un'azienda di tecnologia medica focalizzata sulle tecnologie per il diabete, parteciperà alla BioFuture Conference 2024 che si terrà a New York City dal 28 al 30 ottobre 2024. Paul V. Goode, Presidente e CEO, presenterà il 29 ottobre alle 11:00 ET, fornendo un aggiornamento sullo sviluppo del monitor continuo della glicemia (CBGM) dell'azienda.
La BioFuture Conference esplorerà temi come il calcolo quantistico in biologia, finanziamenti alternativi, intelligenza artificiale nella sanità, psichedelici nei trattamenti per la salute mentale e sfide bioetiche. Relatori di aziende rinomate come Regeneron Pharmaceuticals, IBM e JP Morgan discuteranno dei principali trend che stanno plasmando il futuro della sanità.
Investitori qualificati e media possono fare richiesta per la registrazione gratuita per partecipare alla conferenza, che presenterà oltre 100 esposizioni focalizzate sul futuro.
Glucotrack (Nasdaq: GCTK), una empresa de tecnología médica centrada en tecnologías para la diabetes, participará en la Conferencia BioFuture 2024 en Nueva York del 28 al 30 de octubre de 2024. Paul V. Goode, Presidente y CEO, presentará el 29 de octubre a las 11:00 AM ET, brindando una actualización sobre el desarrollo del monitor continuo de glucosa en sangre (CBGM) de la empresa.
La Conferencia BioFuture explorará temas como la computación cuántica en biología, financiamiento alternativo, inteligencia artificial en la salud, psicodélicos en tratamientos de salud mental y desafíos bioéticos. Ponentes de empresas destacadas como Regeneron Pharmaceuticals, IBM y JP Morgan discutirán las principales tendencias que están dando forma al futuro de la salud.
Inversores calificados y medios de comunicación pueden solicitar registro gratuito para asistir a la conferencia, que contará con más de 100 presentaciones centradas en el futuro.
Glucotrack (Nasdaq: GCTK)는 당뇨병 기술에 집중하는 의료 기술 회사로, 2024년 10월 28일부터 30일까지 뉴욕 시에서 열리는 2024 BioFuture Conference에 참석할 예정입니다. Paul V. Goode 사장兼CEO가 10월 29일 오전 11시(동부 표준시)에 발표하여 회사의 지속 혈당 모니터 (CBGM) 개발에 대한 업데이트를 제공할 것입니다.
BioFuture Conference에서는 생물학의 양자 컴퓨팅, 대체 자금 조달, 의료 분야 인공지능, 정신 건강 치료의 환각제, 생명 윤리적 도전과 같은 주제를 다룰 예정입니다. Regeneron Pharmaceuticals, IBM, JP Morgan과 같은 주요 기업의 발표자들이 의료의 미래를 형성하는 주요 트렌드에 대해 논의할 것입니다.
자격을 갖춘 투자자와 미디어는 100개 이상의 미래 중심 발표가 이루어지는 이 회의에 무료 등록 신청을 할 수 있습니다.
Glucotrack (Nasdaq: GCTK), une entreprise de technologie médicale axée sur les technologies liées au diabète, participera à la Conférence BioFuture 2024 à New York du 28 au 30 octobre 2024. Paul V. Goode, président et PDG, fera une présentation le 29 octobre à 11h00 HAE, fournissant une mise à jour sur le développement de son moniteur de glucose sanguin continu (CBGM).
La Conférence BioFuture explorera des thèmes tels que l'informatique quantique en biologie, le financement alternatif, l'IA dans le secteur de la santé, les psychédéliques dans les traitements de santé mentale et les défis bioéthiques. Des intervenants d'entreprises de renom telles que Regeneron Pharmaceuticals, IBM et JP Morgan discuteront des principales tendances qui façonnent l'avenir des soins de santé.
Les investisseurs qualifiés et les médias peuvent demander une inscription gratuite pour assister à la conférence, qui comportera plus de 100 présentations axées sur l'avenir.
Glucotrack (Nasdaq: GCTK), ein medizinisches Technologieunternehmen, das sich auf Technologien zur Diabetesbehandlung konzentriert, wird an der BioFuture Conference 2024 in New York City vom 28. bis 30. Oktober 2024 teilnehmen. Paul V. Goode, Präsident und CEO, wird am 29. Oktober um 11:00 Uhr ET eine Präsentation halten und ein Update zur Entwicklung des kontinuierlichen Blutzuckermonitors (CBGM) des Unternehmens bereitstellen.
Die BioFuture Conference wird Themen wie Quantencomputing in der Biologie, alternative Finanzierung, KI im Gesundheitswesen, Psychodelika in der Behandlung von psychischen Erkrankungen und bioethische Herausforderungen behandeln. Referenten von prominenten Unternehmen wie Regeneron Pharmaceuticals, IBM und JP Morgan werden über wichtige Trends sprechen, die die Zukunft des Gesundheitswesens prägen.
Zugelassene Investoren und Medienvertreter können sich für eine kostenlose Teilnahme an der Konferenz registrieren, die über 100 zukunftsorientierte Präsentationen bietet.
- None.
- None.
Continuous blood glucose monitor to be among 100+ future-focused presentations at industry investor conference
Rutherford, NJ, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the 2024 BioFuture Conference, to be held at Cure in New York City from October 28-30, 2024.
Paul V. Goode, President & Chief Executive Officer of Glucotrack, will present on Tuesday, October 29, 2024, at 11:00 AM ET and will hold one-on-one meetings. The presentation will provide an update on the development of the Company’s continuous blood glucose monitor (“CBGM”) for people with diabetes. Qualified investors and media are invited to apply for complimentary registration.
This year’s BioFuture program explores topics including next-generation applications of quantum computing and biology, alternative financing, how artificial intelligence (“AI”) will impact healthcare, the use of psychedelics in mental health treatments, bioethical challenges, and more. Speakers from Regeneron Pharmaceuticals, Ipsen, IBM, Rock Health, Ray Therapeutics, Mineralys Therapeutics, Andreessen Horowitz (a16z), and JP Morgan, among many others, will bring insights into the major trends shaping the future of healthcare.
For more information about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
# # #
About BioFuture
BioFuture is where relentless therapeutic pioneers, innovators, and investors gather to assess and shape the future of healthcare and digital health. Participate in candid, unfiltered discussions. At this year’s summit, attendees will explore the exciting convergence between rapidly evolving fields including biopharma, digital medicine, big data, AI, healthcare systems, payors, and more. The coming decade will dramatically accelerate the transformation of the healthcare ecosystem. For more information, please visit www.biofuture.com.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 2+ years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 28, 2024.
Contacts:
Investor Relations:
investors@glucotrack.com
Lisa Wilson
In-Site Communications
T: 917-543-9932
E: lwilson@insitecony.com
Media:
GlucotrackPR@icrinc.com
FAQ
When and where will Glucotrack present at the 2024 BioFuture Conference?
What will Glucotrack's presentation at the BioFuture Conference cover?
Who will be presenting on behalf of Glucotrack at the 2024 BioFuture Conference?
What are some of the topics that will be explored at the 2024 BioFuture Conference?
Can investors attend Glucotrack's presentation at the 2024 BioFuture Conference?
